News | August 14, 2024
Marksans Pharma Q1 FY25 revenue up 18%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Morepen Labs successfully raised Rs. 200 Crore through QIP
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Subscribe To Our Newsletter & Stay Updated
